Every founder in this sector has heard about a down round secondhand this year, quietly, from a mutual investor or a former colleague, rarely from a press release. The public data confirms the pattern is real and larger than the anecdotes suggest, even as the aggregate funding headlines look fine.
The two numbers that do not obviously fit together
CB Insights' Q2 2026 State of Digital Health report found global digital health deal activity at 228 deals in the quarter, a decade low, down 36 percent quarter over quarter and roughly two-thirds below the Q2 2022 peak of 688 deals, even as median deal sizes rose. Meanwhile, Carta's Q1 2026 State of Private Markets report found $30.4 billion raised across the broader venture market in the quarter with fewer down rounds and less dilution than prior periods, but also found that more than 60 percent of that funding went to AI companies specifically, "creating a huge valuation gap for startups" outside that category.
Put those together and the picture resolves: the companies that are still raising are raising on better terms, and a much larger number of companies are simply not raising at all. A market can show falling average dilution and record deal scarcity in the same quarter, because the companies that clear the bar are strong enough to negotiate well, and everyone else is exiting the sample entirely, through a recap, an acquihire, or a quiet wind-down.
Where this shows up specifically
B17 News reported on digital health companies "quietly raising down rounds and closing up shop," describing investors' own account that many healthcare startups were shopping themselves around specifically to avoid an outright shutdown, taking a materially reduced valuation as the price of survival rather than a strategic choice.
The IPO market shows the same dynamic at the largest scale. Hinge Health's May 2025 debut priced as what TechCrunch termed a down-round IPO, a strong first trading day built on a price below the company's last private mark, which tells you the repricing is not confined to distressed late-stage private companies. It reached all the way to some of the most successful exits in the sector's history.
What is actually driving the wave
Three structural forces, not one cyclical dip, are behind this:
- 2021 vintage valuations were priced against a growth multiple environment that no longer exists. Companies that raised at peak multiples in 2021 are now facing a market that reprices growth-stage software, and especially non-AI-labeled healthtech, at a fraction of that multiple.
- Capital concentration into AI and mega-rounds is starving the middle of the market. With over 60 percent of venture dollars flowing to AI broadly, and a growing share of digital health dollars specifically concentrated in mega deals per Rock Health's H1 2026 data, companies that do not fit either pattern are competing for a shrinking remainder.
- Runway extension strategies from 2023 and 2024 are reaching their natural end. Companies that cut burn and extended runway during the reset are now hitting the point where they must raise on real terms, not survive on discipline alone.
What a founder facing this should actually do
Get ahead of the recap conversation rather than reacting to it. A negotiated recap, done from a position of some leverage, with existing investors who want the company to survive, produces a very different outcome than a distressed raise initiated after the company has one quarter of runway left.
Separate your valuation problem from your business problem, honestly. A company with real revenue growth and a bad 2021 valuation is a very different asset than a company with neither, and needs a different conversation with its board. Do not let a painful markdown conversation become an excuse to avoid the harder conversation about whether the underlying business has found its market.
Understand who is actually still buying in your specific category. The data above is not evenly distributed. If you sell into a payer, lean on the strategic venture arms active in your category, they are underwriting differently than a generalist fund evaluating you against an AI-inflated comp set.
The takeaway
The 2026 digital health capital market rewards survival with real revenue and punishes a good story from 2021 with no update since. A quiet recap is not a scandal, it is often the correct decision for a board facing this specific market structure. The mistake is waiting until the runway forces the decision rather than making it with leverage still on your side.
